Literature DB >> 19093225

Caution! Analyze transcripts from conditional knockout alleles.

Shao H Yang1, Martin O Bergo, Emily Farber, Xin Qiao, Loren G Fong, Stephen G Young.   

Abstract

A common strategy for conditional knockout alleles is to "flox" (flank with loxP sites) a 5' exon within the target gene. Typically, the floxed exon does not contain a unit number of codons so that the Cre-mediated recombination event yields a frameshift and a null allele. Documenting recombination within the genomic DNA is often regarded as sufficient proof of a frameshift, and the analysis of transcripts is neglected. We evaluated a previously reported conditional knockout allele for the beta-subunit of protein farnesyltransferase. The recombination event in that allele-the excision of exon 3-was predicted to yield a frameshift. However, following the excision of exon 3, exon 4 was skipped by the mRNA splicing machinery, and the predominant transcript from the mutant allele lacked exon 3 and exon 4 sequences. The "Deltaexon 3-4 transcript" does not contain a frameshift but rather is predicted to encode a protein with a short in-frame deletion. This represents a significant concern when studying an enzyme, since an enzyme with partial function could lead to erroneous conclusions. With thousands of new conditional knockout alleles under construction within mouse mutagenesis consortiums, the protein farnesyltransferase allele holds an important lesson-to characterize knockout alleles at both the DNA and RNA levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19093225      PMCID: PMC2679093          DOI: 10.1007/s11248-008-9237-9

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  18 in total

1.  Using inhibitors of prenylation to block localization and transforming activity.

Authors:  Anastacia C Berzat; Donita C Brady; James J Fiordalisi; Adrienne D Cox
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Critical and distinct roles of amino- and carboxyl-terminal sequences in regulation of the biological activity of the Chp atypical Rho GTPase.

Authors:  Emily J Chenette; Arie Abo; Channing J Der
Journal:  J Biol Chem       Date:  2005-01-21       Impact factor: 5.157

3.  Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.

Authors:  Nieves Mijimolle; Juan Velasco; Pierre Dubus; Carmen Guerra; Carolyn A Weinbaum; Patrick J Casey; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  Transforming activity of the Rho family GTPase, Wrch-1, a Wnt-regulated Cdc42 homolog, is dependent on a novel carboxyl-terminal palmitoylation motif.

Authors:  Anastacia C Berzat; Janice E Buss; Emily J Chenette; Carolyn A Weinbaum; Adam Shutes; Channing J Der; Audrey Minden; Adrienne D Cox
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

5.  A new partner for the international knockout mouse consortium.

Authors:  Francis S Collins; Richard H Finnell; Janet Rossant; Wolfgang Wurst
Journal:  Cell       Date:  2007-04-20       Impact factor: 41.582

6.  Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

Authors:  C A Omer; Z Chen; R E Diehl; M W Conner; H Y Chen; M E Trumbauer; S Gopal-Truter; G Seeburger; H Bhimnathwala; M T Abrams; J P Davide; M S Ellis; J B Gibbs; I Greenberg; K S Koblan; A M Kral; D Liu; R B Lobell; P J Miller; S D Mosser; T J O'Neill; E Rands; M D Schaber; E T Senderak; A Oliff; N E Kohl
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

7.  Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway.

Authors:  Kazutoshi Takahashi; Masato Nakagawa; Stephen G Young; Shinya Yamanaka
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

8.  Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.

Authors:  Shao H Yang; Martin O Bergo; Julia I Toth; Xin Qiao; Yan Hu; Salemiz Sandoval; Margarita Meta; Pravin Bendale; Michael H Gelb; Stephen G Young; Loren G Fong
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

9.  Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.

Authors:  Debra Ferguson; Luis E Rodriguez; Joann P Palma; Marion Refici; Kenneth Jarvis; Jacqueline O'Connor; Gerard M Sullivan; David Frost; Kennan Marsh; Joy Bauch; Haiying Zhang; Nan-Horng Lin; Saul Rosenberg; Hing L Sham; Ingrid B J K Joseph
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

10.  Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.

Authors:  Julia I Toth; Shao H Yang; Xin Qiao; Anne P Beigneux; Michael H Gelb; Casey L Moulson; Jeffrey H Miner; Stephen G Young; Loren G Fong
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

View more
  11 in total

1.  DHHC5 interacts with PDZ domain 3 of post-synaptic density-95 (PSD-95) protein and plays a role in learning and memory.

Authors:  Yi Li; Jie Hu; Klemens Höfer; Andrew M S Wong; Jonathan D Cooper; Shari G Birnbaum; Robert E Hammer; Sandra L Hofmann
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

2.  A conditional knockout resource for the genome-wide study of mouse gene function.

Authors:  William C Skarnes; Barry Rosen; Anthony P West; Manousos Koutsourakis; Wendy Bushell; Vivek Iyer; Alejandro O Mujica; Mark Thomas; Jennifer Harrow; Tony Cox; David Jackson; Jessica Severin; Patrick Biggs; Jun Fu; Michael Nefedov; Pieter J de Jong; A Francis Stewart; Allan Bradley
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

3.  Consequences of Cre-mediated deletion of Ciz1 exon 5 in mice.

Authors:  Jianfeng Xiao; Mohammad Moshahid Khan; Satya Vemula; Jun Tian; Mark S LeDoux
Journal:  FEBS Lett       Date:  2018-08-29       Impact factor: 4.124

4.  Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.

Authors:  Shao H Yang; Sandy Y Chang; Yiping Tu; Gregory W Lawson; Martin O Bergo; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2011-10-28       Impact factor: 5.922

5.  Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.

Authors:  Norbert Berndt; Saïd M Sebti
Journal:  Nat Protoc       Date:  2011-10-27       Impact factor: 13.491

6.  Are B-type lamins essential in all mammalian cells?

Authors:  Shao H Yang; Hea-Jin Jung; Catherine Coffinier; Loren G Fong; Stephen G Young
Journal:  Nucleus       Date:  2011-11-01       Impact factor: 4.197

7.  Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.

Authors:  Meng Liu; Anna-Karin M Sjogren; Christin Karlsson; Mohamed X Ibrahim; Karin M E Andersson; Frida J Olofsson; Annika M Wahlstrom; Martin Dalin; Huiming Yu; Zhenggang Chen; Shao H Yang; Stephen G Young; Martin O Bergo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

8.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

9.  Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.

Authors:  Roger Lee; Sandy Y Chang; Hung Trinh; Yiping Tu; Andrew C White; Brandon S J Davies; Martin O Bergo; Loren G Fong; William E Lowry; Stephen G Young
Journal:  Hum Mol Genet       Date:  2010-01-27       Impact factor: 6.150

10.  Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN).

Authors:  Rudy J Richardson; John K Fink; Paul Glynn; Robert B Hufnagel; Galina F Makhaeva; Sanjeeva J Wijeyesakere
Journal:  Adv Neurotoxicol       Date:  2020-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.